Aspira Women's Health INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Aspira Womens Health Inc. reported continued net losses and substantial doubt about its ability to continue as a going concern, alongside a Nasdaq delisting and termination of a key government funding contract.
Aspira Womens Health Inc. reported a reduced net loss for the second quarter of 2025, driven by significant operating expense reductions, despite a slight revenue decrease and Nasdaq delisting.
Aspira Women's Health reports a slight revenue increase in Q1 2025 but faces going concern doubts amid ongoing losses and a Nasdaq delisting.
Aspira Womens Health reported a net loss of $3.5 million for the third quarter of 2024, while navigating ongoing financial and Nasdaq listing compliance hurdles.
Aspira Women's Health reported its second quarter 2024 results, highlighting a focus on commercial growth, product innovation, and operational efficiency.
Aspira Women's Health reported a net loss of $4.6 million for the first quarter of 2024, while also highlighting progress in product development and commercial strategy.